CoChat

An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism

Open access
Ren, Qingjuan, Chen, Shuchun, Chen, Xing, Niu, Shu, Yue, Lin, Pan, Xiaoyu, Li, Zelin, Chen, Xiaoyi · 2022 · Drug Design, Development and Therapy

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Purpose: This study aimed to investigate the effect of Semaglutide on skeletal muscle and its metabolomics. Methods: A total of 18 male C57BL/6 mice were randomly divided into normal control (NC) group, high-fat diet (HFD) group and HFD+Semaglutide group, and were given standard diet, HFD diet, HFD diet plus Semaglutide, respectively. The body weight, gastrocnemius weight, serum lipid, blood glucose and inflammatory index levels of mice in each group were observed and compared, and the morphological and structural changes of gastrocnemius were also analyzed. Meanwhile, gastrocnemius metabolite changes were analyzed by untargeted metabolomics. Results: After Semaglutide treatment, the food intake and body weight of mice were evidently decreased, while the relative gastrocnemius weight ratio were conversely increased. Meanwhile, the levels of TG, CHO, LDL, HDL, TNF-α, IL-6, IL-1β and HOMA-IR were all observed to decrease remarkably after Semaglutide intervention. Histological analysis showed that Semaglutide significantly improved the pathological changes of gastrocnemius, manifested as increased type I/type II muscle fiber ratio, total muscle fiber area, muscle fiber density, sarcomere length, mitochondrial number and mitochondrial area. Furthermore, metabolic changes of gastrocnemius after Semaglutide intervention were analyzed, and 141 kinds of differential metabolites were screened out, mainly embodied in lipids and organic acids, and enriched in 9 metabolic pathways including a variety of amino acids. Conclusion: Semaglutide can significantly reduce the body weight and the accumulation of intramuscular fat, promote muscle protein synthesis, increase the relative proportion of skeletal muscle, and improve muscle function of obese mice, possibly by altering the metabolism of muscle lipids and organic acids.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dddt.s381546

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Semaglutide significantly reduced food consumption and body weight, and conversely increased gastrocnemius weight in obese mice. (A) The changes of body weight of mice in NC group, the HFD group and the HFD+S group; (B) the food consumption of mice in the HFD+S group and HFD group after Semaglutide treatment; (C) relative gastrocnemius weight in indicated groups; (D) the size of mice in indicated groups. *P < 0.05, **P < 0.01, ***P < 0.001 indicated vs NC group; #P < 0.05, ##P < 0.01 indicated vs HFD group.
Figure 1 Semaglutide significantly reduced food consumption and body weight, and conversely increased gastrocnemius weight in obese mice. (A) The changes of body weight of mice in NC group, the HFD group and the HFD+S group; (B) the food consumption of mice in the HFD+S group and HFD group after Semaglutide treatment; (C) relative gastrocnemius weight in indicated groups; (D) the size of mice in indicated groups. *P < 0.05, **P < 0.01, ***P < 0.001 indicated vs NC group; #P < 0.05, ##P < 0.01 indicated vs HFD group.CC BY-NC · PubMed Central
Figure 2 Semaglutide significantly reduced fasting glucose, lipid and inflammatory indexes. The levels of TG, CHO, LDL, HDL, TNF-α, IL-6, IL-1β and HOMA-IR in different groups were detected. **P < 0.01 or ***P < 0.001 indicated vs NC group; #P < 0.05 or ##P < 0.01 indicated vs HFD group.
Figure 2 Semaglutide significantly reduced fasting glucose, lipid and inflammatory indexes. The levels of TG, CHO, LDL, HDL, TNF-α, IL-6, IL-1β and HOMA-IR in different groups were detected. **P < 0.01 or ***P < 0.001 indicated vs NC group; #P < 0.05 or ##P < 0.01 indicated vs HFD group.CC BY-NC · PubMed Central
Figure 3 Semaglutide significantly improved the lesions and microstructure of gastrocnemius. (A) H&E staining of gastrocnemius tissues; (B) fluorescent labeling of gastrocnemius tissues; (C) the microstructure of gastrocnemius was observed via transmission electron microscopy.
Figure 3 Semaglutide significantly improved the lesions and microstructure of gastrocnemius. (A) H&E staining of gastrocnemius tissues; (B) fluorescent labeling of gastrocnemius tissues; (C) the microstructure of gastrocnemius was observed via transmission electron microscopy.CC BY-NC · PubMed Central
Figure 4 Semaglutide significantly improved the lesions and microstructure of gastrocnemius. Quantitative detection of (A) type I/type II muscle fiber ratio, (B) muscle fiber diameter, (C) total muscle fiber area, (D) muscle fiber density, (E) sarcomere length, (F) sarcoplasmic reticulum area, (G) mitochondrial area, and (H) mitochondrial number. *P < 0.05 or **P < 0.01 or ***P < 0.001 indicated vs NC group; #P < 0.05 or ##P < 0.01 indicated vs HFD group; ns indicated no statistical significance.
Figure 4 Semaglutide significantly improved the lesions and microstructure of gastrocnemius. Quantitative detection of (A) type I/type II muscle fiber ratio, (B) muscle fiber diameter, (C) total muscle fiber area, (D) muscle fiber density, (E) sarcomere length, (F) sarcoplasmic reticulum area, (G) mitochondrial area, and (H) mitochondrial number. *P < 0.05 or **P < 0.01 or ***P < 0.001 indicated vs NC group; #P < 0.05 or ##P < 0.01 indicated vs HFD group; ns indicated no statistical significance.CC BY-NC · PubMed Central
Figure 5 Semaglutide affected gastrocnemius metabolism. (A and B) The OPLS-DA score plot showed that there was a significant separation between the different comparison groups; (C and E) differential metabolites between NC and HFD groups; (D and F) differential metabolites between HFD and HFD+S groups; (G) the enriched pathways between NC and HFD groups; (H) the enriched pathways between HFD and HFD+S groups.
Figure 5 Semaglutide affected gastrocnemius metabolism. (A and B) The OPLS-DA score plot showed that there was a significant separation between the different comparison groups; (C and E) differential metabolites between NC and HFD groups; (D and F) differential metabolites between HFD and HFD+S groups; (G) the enriched pathways between NC and HFD groups; (H) the enriched pathways between HFD and HFD+S groups.CC BY-NC · PubMed Central
Figure 6 Changes of lipid and organic acid metabolites. (A) The difference metabolites of lipids and amino acids were compared between HFD group and NC group; (B) the difference metabolites of lipids and organic acids were compared between HFD+S group and HFD group.
Figure 6 Changes of lipid and organic acid metabolites. (A) The difference metabolites of lipids and amino acids were compared between HFD group and NC group; (B) the difference metabolites of lipids and organic acids were compared between HFD+S group and HFD group.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 2

  1. Christou, 2019, Obesity, 20, 805
  2. Kalra, 2021, J Pak Med Assoc, 71, 1503

Cited by

See all 91

Metadata

Authors
Ren, Q., Chen, S., Chen, X., Niu, S., Yue, L., Pan, X., Li, Z., & Chen, X.
Affiliations
  • Hebei Medical University (CN)
  • First Hospital of Shijiazhuang (CN)
  • Third Hospital of Hebei Medical University (CN)
Corresponding author
Chen, Shuchun
Venue
Drug Design, Development and Therapy
Published
2022-10
Volume
Volume 16
Pages
3723-3735
ISSN
1177-8881 (ISSN-L)
OpenAlex
W4307377238
Cited by
91
References
41
Citations by year
2026: 18 · 2025: 43 · 2024: 20 · 2023: 10
FWCI
5.96
Type
journal article
Language
en
Open access
Locations
  • Drug Design Development and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
semaglutide, GLP-1 receptor agonists, sarcopenic obesity, skeletal muscle metabolism, gastrocnemius, high-fat diet, intramuscular fat, muscle fiber composition, mitochondrial density, muscle metabolomics, lipid metabolism, amino acid metabolism, insulin resistance, inflammation, muscle protein synthesis
MeSH terms
Glucagon-Like Peptide-1 Receptor, Semaglutide, Animals, Lipids, Male, Mice, Inbred C57BL, Mice, Obese, Obesity, Muscle, Skeletal, Mice, Sarcopenia, Diet, High-Fat

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism. https://app.cochat.ai/papers/10.2147/dddt.s381546
The paper
Ren, Q., Chen, S., Chen, X., Niu, S., Yue, L., Pan, X., Li, Z., & Chen, X. (2022). An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s381546

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.